1. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367-1384. doi:10.1053/gast.2002.36061
2. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2009;136(2):477-485.e11. doi:10.1053/j.gastro.2008.10.052
3. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem. 2007;53(5):940-946. doi:10.1373/clinchem.2006.081620
4. Fraser A, Thinggaard M, Christensen K, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int. 2009;29(10):1494-1499. doi:10.1111/j.1478-3231.2009.02090.x
5. Oh C-M, Won Y-J, Cho H, et al. Alanine aminotransferase and gamma-glutamyl transferase have different dose-response relationships with risk of mortality by age. Liver International. 2016;36(1):126-135. doi:10.1111/liv.12879
6. Ruhl CE, Everhart JE. Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology. 2010;138(4):1346-1356, 1356.e1-3. doi:10.1053/j.gastro.2009.12.053
7. Iwasaki T, Yoneda M, Kawasaki S, Fujita K, Nakajima A, Terauchi Y. Hepatic fat content-independent association of the serum level of gamma-glutamyltransferase with visceral adiposity, but not subcutaneous adiposity. Diabetes Res Clin Pract. 2008;79(1):e13-14. doi:10.1016/j.diabres.2007.06.014
8. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(1):127-133. doi:10.1161/01.ATV.0000251993.20372.40
9. Liu Z, Que S, Ning H, Wang L, Peng T. Elevated alanine aminotransferase is strongly associated with incident metabolic syndrome: a meta-analysis of prospective studies. PLoS One. 2013;8(12):e80596. doi:10.1371/journal.pone.0080596
10. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:https://doi.org/10.1002/hep.29367
11. Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329-341. doi:10.1016/j.jhepr.2019.08.002
12. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. doi:10.1038/ajg.2016.517
13. Tariq R, Axley P, Singal AK. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. J Clin Exp Hepatol. 2020;10(1):81-87. doi:10.1016/j.jceh.2019.07.008
14. VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15(2):75-85. doi:10.1007/s11901-016-0295-9
15. Ding W, Fan J, Qin J. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(1):322-333.
16. Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018;67(5):1726-1736. doi:10.1002/hep.29546
17. Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. doi:10.1038/s41591-019-0675-0
18. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41. doi:10.1016/j.immuni.2019.06.025
19. Thompson PA, Khatami M, Baglole CJ, et al. Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis. 2015;36(Suppl 1):S232-S253. doi:10.1093/carcin/bgv038
20. Liu Z, Ning H, Que S, Wang L, Qin X, Peng T. Complex association between alanine aminotransferase activity and mortality in general population: a systematic review and meta-analysis of prospective studies. PLoS One. 2014;9(3):e91410. doi:10.1371/journal.pone.0091410
21. Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):187-201. doi:10.1093/ije/dyt192
22. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328(7446):983. doi:10.1136/bmj.38050.593634.63
23. Mazza A, Casiglia E, Scarpa R, et al. Predictors of cancer mortality in elderly subjects. Eur J Epidemiol. 1999;15(5):421-427. doi:10.1023/a:1007543725207
24. Strasak AM, Rapp K, Brant LJ, et al. Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res. 2008;68(10):3970-3977. doi:10.1158/0008-5472.CAN-07-6686
25. Strasak AM, Pfeiffer RM, Klenk J, et al. Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. International Journal of Cancer. 2008;123(8):1902-1906. doi:10.1002/ijc.23714
26. Kunutsor SK, Apekey TA, Van Hemelrijck M, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int J Cancer. 2015;136(5):1162-1170. doi:10.1002/ijc.29084
27. Sondik EJ, Madans JH, Rothwell CJ. National Center for Health Statistics. :71.
28. Thiébaut ACM, Bénichou J. Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med. 2004;23(24):3803-3820. doi:10.1002/sim.2098
29. Bigaard J, Frederiksen K, Tjønneland A, et al. Body fat and fat-free mass and all-cause mortality. Obes Res. 2004;12(7):1042-1049. doi:10.1038/oby.2004.131
30. Fisher AL. Of worms and women: sarcopenia and its role in disability and mortality. J Am Geriatr Soc. 2004;52(7):1185-1190. doi:10.1111/j.1532-5415.2004.52320.x
31. Le Couteur DG, Blyth FM, Creasey HM, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010;65(7):712-717. doi:10.1093/gerona/glq082
32. Elinav E, Ackerman Z, Maaravi Y, Ben-Dov IZ, Ein-Mor E, Stessman J. Low alanine aminotransferase activity in older people is associated with greater long-term mortality. J Am Geriatr Soc. 2006;54(11):1719-1724. doi:10.1111/j.1532-5415.2006.00921.x
33. Meisinger C, Döring A, Schneider A, Löwel H, KORA Study Group. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis. 2006;189(2):297-302. doi:10.1016/j.atherosclerosis.2006.01.010
34. Park JH, Watt DG, Roxburgh CSD, Horgan PG, McMillan DC. Colorectal Cancer, Systemic Inflammation, and Outcome: Staging the Tumor and Staging the Host. Ann Surg. 2016;263(2):326-336. doi:10.1097/SLA.0000000000001122
35. Stocken DD, Hassan AB, Altman DG, et al. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99(6):883-893. doi:10.1038/sj.bjc.6604568
36. Toiyama Y, Inoue Y, Saigusa S, et al. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res. 2013;33(11):5065-5074.
37. Zhong C, You S, Chen J, et al. Serum Alkaline Phosphatase, Phosphate, and In-Hospital Mortality in Acute Ischemic Stroke Patients. Journal of Stroke and Cerebrovascular Diseases. 2018;27(1):257-266. doi:10.1016/j.jstrokecerebrovasdis.2017.08.041
38. Sakuta H, Suzuki T, Yasuda H, Ito T. Gamma-glutamyl transferase and metabolic risk factors for cardiovascular disease. Intern Med. 2005;44(6):538-541. doi:10.2169/internalmedicine.44.538
39. Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990;61(4):597-604. doi:10.1038/bjc.1990.133
40. Thornburg JM, Nelson KK, Clem BF, et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 2008;10(5):R84. doi:10.1186/bcr2154
41. Hao H, Chen L, Huang D, Ge J, Qiu Y, Hao L. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma. European Journal of Cancer Care. 2017;26(5):e12536. doi:10.1111/ecc.12536
42. Karaphillis E, Goldstein R, Murphy S, Qayyum R. Serum alanine aminotransferase levels and all-cause mortality. Eur J Gastroenterol Hepatol. 2017;29(3):284-288. doi:10.1097/MEG.0000000000000778
43. Lee H, Shin DW, Lee TH, et al. Association Between Change in Serum Aminotransferase and Mortality: A Nationwide Cohort Study in Korea. Medicine. 2016;95(12):e3158. doi:10.1097/MD.0000000000003158
44. Lindmark G, Gerdin B, Påhlman L, Bergström R, Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum. 1994;37(12):1219-1227. doi:10.1007/bf02257785